There are 2789 resources available
739P - Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
Presenter: Renaud Sabatier
Session: ePoster Display
740P - Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
Presenter: Kristina Lindemann
Session: ePoster Display
741P - Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
Presenter: Louis Mourani
Session: ePoster Display
742P - Survival in patients (pts) with advanced ovarian cancer (AOC) changes with cumulative number of risk factors (RFs): A US real-world (RW) analysis
Presenter: Dana Chase
Session: ePoster Display
792P - Analysis of postoperative adjuvant chemotherapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study
Presenter: Shin Nishio
Session: ePoster Display
793P - Comparison of two high-dose rate (HDR) brachytherapy regimens in treatment of cervical cancer
Presenter: Abhishek Krishna
Session: ePoster Display
Resources:
Abstract
794P - Comparative study of effectiveness of Pap smear and visual inspection with acetic acid for screening of premalignant and malignant lesion of cervix in a tertiary care setup
Presenter: Meena Kakollu
Session: ePoster Display
796P - Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
Presenter: Vicky Makker
Session: ePoster Display
798P - A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001
Presenter: Lorena Fariñas-Madrid
Session: ePoster Display